How Many ImmunoGen, Inc. (NASDAQ:IMGN)'s Analysts Are Bullish?

How Many ImmunoGen, Inc. (NASDAQ:IMGN)'s Analysts Are Bullish?

ImmunoGen, Inc. is a clinical-stage biotechnology firm focused on the development of targeted anticancer therapeutics. The company has a market cap of $593.46 million. The Company's clinical and preclinical product candidates are antibody-drug …

(Visited 1 times, 1 visits today)
7
Like
Save

Comments

Comments are disabled for this post.